A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH

被引:57
作者
Roylance, R.
Gorman, P.
Papior, T.
Wan, Y-L
Ives, M.
Watson, J. E.
Collins, C.
Wortham, N.
Langford, C.
Fiegler, H.
Carter, N.
Gillett, C.
Sasieni, P.
Pinder, S.
Hanby, A.
Tomlinson, I.
机构
[1] Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England
[2] UCSF, Collins Lab, S151, Ctr Canc, San Francisco, CA USA
[3] Wellcome Trust Sanger Inst, Cambridge, England
[4] Guys Hosp, CRUK Breast Pathol Lab, London SE1 9RT, England
[5] Barts & London Med Sch, London, England
[6] Addenbrookes Hosp, Dept Histopathol, Cambridge, England
[7] St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England
[8] Univ Leeds, Acad Unit Pathol, Leeds LS2 9JT, W Yorkshire, England
基金
英国惠康基金;
关键词
array CGH; Chromosome; 169; breast cancer;
D O I
10.1038/sj.onc.1209659
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We analysed chromosome 16q in 106 breast cancers using tiling-path array-comparative genomic hybridization (aCGH). About 80% of ductal cancers (IDCs) and all lobular cancers (ILCs) lost at least part of 16q. Grade I (GI) IDCs and ILCs often lost the whole chromosome arm. Grade II (GII) and grade III ( GIII) IDCs showed less frequent whole-arm loss, but often had complex changes, typically small regions of gain together with larger regions of loss. The boundaries of gains/losses tended to cluster, common sites being 54.5-55.5 Mb and 57.4-58.8 Mb. Overall, the peak frequency of loss (83% cancers) occurred at 61.9-62.9 Mb. We also found several 'minimal' regions of loss/gain. However, no mutations in candidate genes (TRADD, CDH5, CDH8 and CDH11) were detected. Cluster analysis based on copy number changes identified a large group of cancers that had lost most of 16q, and two smaller groups ( one with few changes, one with a tendency to show copy number gain). Although all morphological types occurred in each cluster group, IDCs ( especially GII/GIII) were relatively over-represented in the smaller groups. Cluster groups were not independently associated with survival. Use of tiling-path aCGH prompted re-evaluation of the hypothetical pathways of breast carcinogenesis. ILCs have the simplest changes on 16q and probably diverge from the IDC lineage close to the stage of 16q loss. Higher-grade IDCs probably develop from low-grade lesions in most cases, but there remains evidence that some GII/GIII IDCs arise without a GI precursor.
引用
收藏
页码:6544 / 6553
页数:10
相关论文
共 38 条
[1]   The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients [J].
Barnes, DM ;
Millis, RR ;
Gillett, CE ;
Ryder, K ;
Skilton, D ;
Fentiman, IS ;
Rubens, RD .
ENDOCRINE-RELATED CANCER, 2004, 11 (01) :85-96
[2]  
Berx G, 1996, ONCOGENE, V13, P1919
[3]   E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers [J].
Berx, G ;
CletonJansen, AM ;
Nollet, F ;
deLeeuw, WJF ;
vandeVijver, MJ ;
Cornelisse, C ;
vanRoy, F .
EMBO JOURNAL, 1995, 14 (24) :6107-6115
[4]  
Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO
[5]  
2-B
[6]   Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer [J].
Cleton-Jansen, AM ;
Buerger, H ;
ter Haar, N ;
Philippo, K ;
van de Vijver, MJ ;
Boecker, W ;
Smit, VTHBM ;
Cornelisse, CJ .
GENES CHROMOSOMES & CANCER, 2004, 41 (02) :109-116
[7]   E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? [J].
Cleton-Jansen, AM .
BREAST CANCER RESEARCH, 2002, 4 (01) :5-8
[8]   Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3 [J].
Cleton-Jansen, AM ;
Moerland, EW ;
Pronk, JC ;
van Berkel, CGM ;
Apostolou, S ;
Crawford, J ;
Savoia, A ;
Auerbach, AD ;
Mathew, CG ;
Callen, DF ;
Cornelisse, CJ .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1049-1052
[9]  
Cleton-Jansen AM, 2001, CANCER RES, V61, P1171
[10]  
Cooper LS, 1999, CANCER-AM CANCER SOC, V86, P2053, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2053::AID-CNCR24>3.0.CO